3D pharmacophore-based discovery of novel Kv10.1 inhibitors with antiproliferative activity

Toplak, Žan (avtor), Hendrickx, Louise Antonia (avtor), Gubič, Špela (avtor), Možina, Štefan (avtor), Žegura, Bojana (avtor), Štern, Alja (avtor), Novak, Matjaž (avtor), Shi, Xiaoyi (avtor), Peigneur, Steve (avtor), Tytgat, Jan (avtor), Tomašič, Tihomir (avtor), Pardo, Luis A. (avtor), Peterlin-Mašič, Lucija (avtor)

(1) Background: The voltage-gated potassium channel K$_V$10.1 (Eag1) is considered a near- universal tumour marker and represents a promising new target for the discovery of novel anticancer drugs. (2) Methods: We utilized the ligand-based drug discovery methodology using 3D pharmacophore modelling and medicinal chemistry approaches to prepare a novel structural class of K$_V$10.1 inhibitors. Whole-cell patch clamp experiments were used to investigate potency, selectivity, kinetics and mode of inhibition. Anticancer activity was determined using 2D and 3D cell-based models. (3) Results: The virtual screening hit compound ZVS-08 discovered by 3D pharmacophore modelling exhibited an IC$_{50}$ value of 3.70 µM against K$_V$10.1 and inhibited the channel in a voltagedependent manner consistent with the action of a gating modifier. Structural optimization resulted in the most potent K$_V$10.1 inhibitor of the series with an IC$_{50}$ value of 740 nM, which was potent on the MCF-7 cell line expressing high K$_V$10.1 levels and low hERG levels, induced significant apoptosis in tumour spheroids of Colo-357 cells and was not mutagenic. (4) Conclusions: Computational ligand-based drug design methods can be successful in the discovery of new potent K$_V$10.1 inhibitors. The main problem in the field of K$_V$10.1 inhibitors remains selectivity against the hERG channel, which needs to be addressed in the future also with target-based drug design methods.

• Jezik: Angleški jezik
• Ključne besede: K$_V$10.1, ion channels, hERG, pharmacophore modelling, virtual screening, antiproliferative activity
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: 24 str.
• Številčenje: Vol. 13, iss. 6, art. 1244
• PID: 20.500.12556/RUL-134993
• UDK: 615.4:54:616-006
• ISSN pri članku: 2072-6694
• DOI: 10.3390/cancers13061244
• COBISS.SI-ID: 55144451
• Datum objave v RUL: 16.02.2022

Gradivo je del revije

• Naslov: Cancers
• Skrajšan naslov: Cancers
• Založnik: MDPI
• ISSN: 2072-6694
• COBISS.SI-ID: 517914137

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 12.03.2021

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: K$_V$10.1, ionski kanal, tumorski markerji, farmakoforno modeliranje, virtualno rešetanje, antiproliferativno delovanje, farmacevtska kemija, tumorski označevalci